Anti-TGF beta 2 Propeptide antibody
Specifications
| Product Cat#: | AB-06-4318 |
| Product type: | Primary antibody |
| Antigen: | TGF beta 2 Propeptide |
| Immunogen: | KLH conjugated synthetic peptide derived from human TGF-beta 2 154-197/414 |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:400-1:2000); Immunohistochemistry-Paraffin (1:500-1:800) |
| Reactivity: | Human, Mouse, Rat, Rabbit |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | 10 mM Tris-HCl buffer (pH7.4), 1% BSA, 50% glycerol, 0.03% Proclin. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | BSC 1 cell growth inhibitor |
| BSC1 cell growth inhibitor | |
| Cetermin | |
| G TSF | |
| Glioblastoma derived T cell suppressor | |
| Glioblastoma derived T cell suppressor factor | |
| GTSF | |
| MGC116892 | |
| Polyergin | |
| TGF B2 | |
| TGF beta2 | |
| TGFB 2 | |
| TGFB2 | |
| Transforming growth factor beta 2.TGF B2 | |
| BSC 1 cell growth inhibitor | |
| BSC-1 cell growth inhibitor | |
| BSC1 cell growth inhibitor | |
| Cetermin | |
| G TSF | |
| G-TSF | |
| Glioblastoma derived T cell suppressor | |
| Glioblastoma derived T cell suppressor factor | |
| Glioblastoma-derived T-cell suppressor factor | |
| GTSF | |
| MGC116892 | |
| Polyergin | |
| TGF beta2 | |
| TGF-beta-2 | |
| TGF-beta2 | |
| TGFB 2 | |
| TGFB2 | |
| TGFB2_HUMAN | |
| Transforming growth factor beta 2 |
Show More
Target information
Transforming growth factor beta-2 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively.
Latency-associated peptide: Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix (By similarity). Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with ‘milieu molecules’, such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2 (By similarity).
Provider
Erpantech Laboratory
